Treatment Goals Have Changed
Historically, IBD treatment aimed for symptom control — feeling better was the endpoint. Modern treat-to-target strategies set higher bars: endoscopic mucosal healing, biomarker normalisation (calprotectin below 150, CRP normalisation), and increasingly histological remission. This shift means that treatment reassessment is driven by objective measures, not just how you feel.
Signs That Treatment May Need Adjustment
Rising calprotectin despite stable symptoms — subclinical inflammation may be accumulating, risking structural damage. Persistent symptoms despite medication adherence — the current therapy may have reached its ceiling of efficacy. New or worsening extraintestinal manifestations — joint pain, skin lesions, or eye inflammation. Corticosteroid dependency — needing steroids more than once per year to maintain remission indicates inadequate maintenance therapy. Biomarker discordance — normal calprotectin but persistent symptoms may indicate coexisting IBS or bile acid malabsorption rather than treatment failure.
Escalation Pathways
IBD therapeutics follow a step-up (starting mild, escalating as needed) or top-down (starting intensive, de-escalating after remission) approach. The treatment ladder typically moves from 5-ASA (UC) through immunomodulators (azathioprine, methotrexate) to biologics (anti-TNF, anti-integrin, anti-IL-12/23, anti-IL-23) and small molecules (JAK inhibitors, S1P modulators). Switching within a drug class (e.g., from one anti-TNF to another) or between classes is guided by mechanism of failure: primary non-response (the drug never worked) suggests a class switch, while secondary loss of response (the drug worked then stopped) may warrant dose optimisation, antibody testing, or class switch.
Therapeutic Drug Monitoring
Biologic drug levels and anti-drug antibodies can be measured through blood tests to guide dose adjustments. Sub-therapeutic drug levels with high anti-drug antibodies suggest immunogenic loss of response — treated by adding an immunomodulator or switching biologics. Sub-therapeutic levels without antibodies suggest a pharmacokinetic issue — treated by dose escalation. Adequate drug levels with active disease suggest mechanistic failure — requiring a class switch.
Patient Participation
Treatment decisions in IBD are complex, involve risk-benefit trade-offs, and affect quality of life. Shared decision-making — where your gastroenterologist explains the options and you participate in choosing the path forward — produces better adherence, satisfaction, and outcomes. Prepare for treatment discussions by: understanding your current therapy and its targets, knowing your latest biomarker trends, listing your current symptoms and their impact, and being clear about your priorities (convenience, side effect profile, speed of onset).
Surgery Is an Option, Not a Defeat
In refractory IBD, surgery (colectomy in UC, resection in Crohn's) can dramatically improve quality of life. It is not a failure of medical therapy — it is a valid treatment option that should be discussed early, not only as a last resort.